Does granulocyte colony-stimulating factor ameliorate the proinflammatory response in human meningococcal septic shock?

Critical Care Medicine

Volumn 36, Issue 9, 2008, Pages 2583-2589

  Rojahn, Astrid ^a   Brusletto, Berit ^a   Øvstebø, Reidun ^a   Haug, Kari B F ^a   Kierulf, Peter ^a,b   Brandtzaeg, Petter ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Granulocyte colony stimulating factor; Interleukin 10; Lipopolysaccharide; Monocytes; Neisseria meningitidis DNA; Septic shock; Tumor necrosis factor

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; BACTERIAL DNA; DOPAMINE; ENDOTOXIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; NORADRENALIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD LEVEL; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EXPERIMENTAL STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INFANT; LABORATORY; MALE; MENINGOCOCCEMIA; MONITORING; MONOCYTE; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; PROTEIN SECRETION; UNIVERSITY HOSPITAL; BIOSYNTHESIS; BLOOD; DRUG EFFECT; IN VITRO STUDY; INFLAMMATION; MENINGOCOCCOSIS; METABOLISM; MICROBIOLOGY; PRESCHOOL CHILD; SEPTIC SHOCK;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFANT; INFLAMMATION; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MALE; MENINGOCOCCAL INFECTIONS; MONOCYTES; NEISSERIA MENINGITIDIS; RECOMBINANT PROTEINS; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 53049089553     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181844399     Document Type: Article

References (38)

1. Brandtzaeg P, Osnes L, Ovstebo R, et al: Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: Identification of interleu-kin-10 as a major functional deactivator of human monocytes. J Exp Med 1996; 184: 51-60
2. Bjerre A, Brusletto B, Ovstebo R, et al: Identification of meningococcal LPS as a major monocyte activator in IL-10 depleted shock plasmas and CSF by blocking the CD14-TLR4 receptor complex. J Endotoxin Res 2003; 9:155-163
3. Boneberg EM, Hareng L, Gantner F, et al: Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma. Blood 2000; 95: 270-276
4. Saito M, Kiyokawa N, Taguchi T, et al: Granu-locyte colony-stimulating factor directly affects human monocytes and modulates cytokine secretion. Exp Hematol 2002; 30:1115-1123
5. Busch CJ, Wanner GA, Menger MD, et al: Gran-ulocyte colony-stimulating factor (G-CSF) reduces not only gram-negative but also gram-positive infection-associated proinflammatory cytokine release by interaction between Kupffer cells and leukocytes. Inflamm Res 2004; 53:205-210
6. Fink MP, O'Sullivan BP, Menconi MJ, et al: Effect of granulocyte colony-stimulating factor on systemic and pulmonary responses to endo-toxin in pigs. J Trauma 1993; 34:571-577
7. Gorgen I, Hartung T, Leist M, et al: Granu-locyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha. J Immunol 1992; 149:918-924
8. Hartung T, Docke WD, Gantner F, et al: Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995; 85:2482-2489
9. Pajkrt D, Manten A, van der Poll T, et al: Modulation of cytokine release and neutro-phil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 1997; 90:1415-1424
10. Brandtzaeg P, Kierulf P, Gaustad P, et al: Plasma endotoxin as predictor of multiple organ failure and death in systemic meningococ-cal disease. J Infect Dis 1989; 159:195-204
11. Ovstebo R, Brandtzaeg P, Brusletto B, et al: Use of robotized DNA isolation and real-time PCR to quantify and identify close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease. J Clin Microbiol 2004; 42:2980-2987
12. Waage A, Brandtzaeg P, Halstensen A, et al: The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989; 169:333-338
13. Brandtzaeg P, Bryn K, Kierulf P, et al: Me-ningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy. J Clin Invest 1992; 89: 816-823
14. Brandtzaeg P: Pathogenesis and pathophysi-ology of meningococcal disease. In: Menin-gococcal Disease, Pathogenicity and Prevention. Frosch M, Maiden M (Eds). Weinheim, Wiley-VCH Verlag, 2006, pp 427-480
15. Moller AS, Bjerre A, Brusletto B, et al: Chemokine patterns in meningococcal disease. J Infect Dis 2005; 191:768-775
16. Bjerre A, Brusletto B, Hoiby EA, et al: Plasma interferon-γ and interleukin 10 levels in systemic meningococcal disease compared with severe gram-positive septic shock. Crit Care Med 2004; 32:433-438
17. Brandtzaeg P, Bjerre A, Øvstebo R, et al: Neisseria meningitidis lipopolysaccharides in human pathology. J Endotoxin Res 2001; 7:401-420
18. Brandtzaeg P, Mollnes TE, Kierulf P: Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 1989; 160:58-65
19. Brandtzaeg P, Hogasen K, Kierulf P, et al: The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation. J Infect Dis 1996; 173: 647-655
20. Brandtzaeg P, Ovstebo R, Kierulf P: Quantitative detection of bacterial lipopolysaccharides in clinical specimens. In: Meningococcal Disease: Methods and Protocols. Pollard AJ, Maiden MCJ (Eds). Totowa, NJ, Humana Press, 2001, pp 427-439
21. Osnes LT, Westvik AB, Kierulf P: Procoagu-lant and profibrinolytic activities of cryopre-served human monocytes. Thromb Res 1994; 76:373-383
22. Waring PM, Presneill J, Maher DW, et al: Differential alterations in plasma colony-stimulating factor concentrations in menin-gococcaemia. Clin Exp Immunol 1995; 102: 501-506
23. van der Kaay DC, de Kleijn ED, de Rijke YB, et al: Procalcitonin as a prognostic marker in meningococcal disease. Intensive Care Med 2002; 28:1606-1612
24. Carrol ED, Newland P, Thomson AP, et al: Prognostic value of procalcitonin in children with meningococcal sepsis. Crit Care Med 2005; 33:224-225
25. van Deuren M, van der Ven-Jongekrijg J, Bartelink AK, et al: Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J Infect Dis 1995; 172:433-439
26. Hazelzet JA, Risseeuw-Appel IM, Kornelisse RF, et al: Age-related differences in outcome and severity of DIC in children with septic shock and purpura. Thromb Haemost 1996; 76:932-938
27. Derkx B, Marchant A, Goldman M, et al: High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 1995; 171:229-232
28. Lehmann AK, Halstensen A, Sornes S, et al: High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun 1995; 63:2109-2112
29. Namork E, Brandtzaeg P. Fatal meningococcal septicaemia with "blebing" meningococ-cus. Lancet 2002; 260:1741
30. Post DM, Zhang D, Eastvold JS, et al: Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B. J Biol Chem 2005; 280:38383-38394
31. Brandtzaeg P, Kierulf P: Endotoxin and me-ningococcemia. Intravascular inflammation induced by native endotoxin in man. In: Bacterial Endotoxic Lipopolyosaccharides. Vol. 2. Immunopharmacology and Pathophysiol-ogy. Ryan JL, Morrison DC (Eds). Boca Raton, CRC Press, 1992, pp 327-346
32. Wagner JL, Hugli TE: Radioimmunoassay for anaphylotoxins: A sensitive method for determining complement activation products in biological fluids. Anal Biochem 1984; 136: 75-88
33. Pixley RA, de La Cadena R, Page JD, et al: The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91:61-68
34. Mollnes TE, Redl H, Hogasen K, et al: Complement activation in septic baboons detected by neoepitope-specific assays for C3b/ iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol 1993; 91:295-300
35. Hazelzet JA, de Groot R, van Mierlo G, et al: Complement activation in relation to capillary leakage in children with septic shock and purpura. Infect Immun 1998; 66: 5350-5356
36. Brandtzaeg P, Waage A, Mollnes TE, et al: Severe septic shock involves more than tumor necrosis factor. In: Bacterial Endotox-ins: Cytokine Mediators and New Therapy for Sepsis. Sturk A, van Deventer SJH, ten Cate JW, et al. (Eds). New York, Wiley-Liss, 1991, pp 25-42
37. Sprong T, Brandtzaeg P, Fung M, et al: Inhibition of C5a-induced inflammation with perserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood 2003; 102: 3702-3710
38. Baines PB, Standford S, Bishop-Bailey D, et al: Nitric oxide production in meningococcal disease is directly related to disease severity. Crit Care Med 1999; 27:1187-1190